Skip to main content

Table 1 Comparison of mean absorbance level and mean antibody titers with standard deviation (SD) of anti-HPV16 and HPV18 antibodies between non-smokers and smokers by vaccination group

From: Impact of smoking on the quantity and quality of antibodies induced by human papillomavirus type 16 and 18 AS04-adjuvanted virus-like-particle vaccine – a pilot study

 

HPV vaccine (n = 103)

HAV vaccine (n = 113)

 

Non-smokers (n = 55)* mean (±SD)

Smokers (n = 48)* mean (±SD)

p-value†

Non-smokers (n = 49)* mean (±SD)

Smokers (n = 64)* mean (±SD)

p-value†

HPV16

Antibody absorbance

Baseline

0.12 (±0.08)

0.29 (±0.52)

0.2

0.21 (±0.43)

0.18 (±0.29 )

0.9

Month 7

1.97 (±0.78)

1.88 (±0.73)

0.4

0.01 (±0.04)

0.01 (±0.02)

0.7

HPV18

Antibody absorbance

Baseline

0.07 (±0.06)

0.18 (±0.008)

0.1

0.1 (±0.08)

0.10 (±0.14)

0.8

Month 7

1.44 (±0.85)

1.36 (±0.76)

0.6

0.01(±0.03)

0.01 (±0.03)

0.7

  1. *Non-smokers (Cotinine <20 ng/ml) and smokers (cotinine > =20 ng/ml).
  2. p-value derived from Mann–Whitney test to evaluate mean absorbance difference between non-smokers and smokers.